Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ferring Pharmaceuticals, a biopharmaceutical company, and its affiliate Ferring Research Institute have opened a new and expanded, 38,000-square-foot facility located in Sorrento Valley, San Diego that will be dedicated to further development of peptide research and therapeutics.
Subscribe to our email newsletter
The new San Diego research facility now houses expanded research laboratories for peptide medicinal chemistry, bioanalytical and DMPK (distribution, metabolism and Pharmacokinetics), molecular and cell biology, cell culture, in vitro and in vivo pharmacology.
Degarelix, a new prostate cancer drug, is the first peptide new chemical entity discovered by Ferring Research Institute in San Diego and developed globally by Ferring Pharmaceuticals. Ferring is preparing to launch degarelix in the US in the first quarter of 2009.
Frederik Paulsen, chairman of Ferring Pharmaceuticals, said: Historically, Ferring is one of the first pharmaceutical companies to have embarked upon peptide research. It is an integral part of our heritage and it is part of our vision today that our Research Institute in San Diego will take this heritage into the future.
The most pertinent example of the strength and promise of peptide therapy is our new prostate cancer treatment, degarelix. The research towards degarelix occurred in San Diego with our institute and academic research partners.